Tag Archives: Pharmaceutical Benefits Scheme

Relief for patients with cystic fibrosis

Vertex Pharmaceuticals has announced that Symdeko (tezacaftor/ivacaftor and ivacaftor) is now conditionally reimbursed in Australia for people with cystic fibrosis (CF) aged 12 and over. To be reimbursed, patients must be homozygous for the F508del mutation or have one copy of the F508del mutation and another responsive residual function mutation in the cystic fibrosis …

Read More »

Health spend tracking at below inflation rate

More than $185 billion, or almost $7,500 per person, was spent on health goods and services in Australia during 2017-18, according to a new report by the Australian Institute of Health and Welfare (AIHW). The report, ‘Health expenditure in Australia 2017-18’, reveals spending per person decreased by 0.4 per cent, …

Read More »

Monthly dosing of Opdivo available on PBS

Bristol-Myers Squibb has announced that patients undergoing immuno-oncology (IO) treatment will now have access to a monthly dosing schedule of Opdivo (nivolumab) via the Pharmaceutical Benefits Scheme (PBS) for a range of cancers. Effective from this month, the PBS listing will provide healthcare professionals with the option to prescribe Opdivo …

Read More »

Botox listed on PBS from September

Botox (botulinum toxin type A) injection is now listed on the Pharmaceutical Benefits Scheme (PBS) for moderate-to-severe lower-limb spasticity following an acute event, such as stroke, traumatic brain injury and spinal cord injury. The PBS listing is seen to be an important development for survivors of neurological events who are …

Read More »

Asthma treatment option for PBS reimbursement

Since August 1, new once-daily asthma treatment option Arnuity Ellipta is being reimbursed on the PBS, according to GSK Australia. The listing provides “affordable access to another treatment option for suitable asthma patients aged 12 years and over”. “This new once-daily inhaler adds to the treatment options available to patients, …

Read More »

Health Minister gets Biosimilar Week underway

The Official opening of Biosimilar Week, running from April 29 to May 3 featured a statement on the role of biosimilar medicines in a sustainable health system by Health Minister Greg Hunt. Mr Hunt began by welcoming delegates to the Generic and Biosimilar Medicines Association (GBMA), Biosimilar Grants and Biosimilar …

Read More »

Guild President’s fierce response

Pharmacy Guild of Australia’s National President George Tambassis has penned a passionate open letter to raise awareness of the dangers of tinkering unnecessarily with the PBS. In particular, Mr Tambassis raises serious concerns over the recently proposed idea to increase quantities of routinely dispensed medicines. Below is Mr Tambassis’ 26th …

Read More »